Dr. Jeffrey Ulmer received his B.Sc. with honors from the Department of Chemistry at the University of Regina and was the recipient of the Merit Award of the Society of Chemical Industry of Canada. He received his Ph.D. in biochemistry from McGill University and completed his postdoctoral training in the laboratory of Nobel laureate Dr. George Palade in the Department of Cell Biology at Yale University School of Medicine. At Merck Research Laboratories, Chiron Corporation and Novartis Vaccines he conducted seminal studies on nucleic acid vaccines and novel vaccine adjuvants/delivery systems. He has published over 200 scientific articles, is on the editorial boards of Expert Opinion on Biological Therapy, Human Vaccines, and Expert Review of Vaccines. He is currently Head, Preclinical R&D, GSK Vaccines.

 John Trainer is the leader of AstraZeneca’s Partnering and Strategy group, which focuses on business deals ranging from acquisitions and clinical collaborations to licensing agreements and new industry partnerships. 

John has held several leadership positions with MedImmune and AstraZeneca during his 14+ years with the company. Previous to this role he was Vice President, Corporate Development for AstraZeneca and earlier the Head for Infection, Neuroscience and Gastrointestinal (ING) medicines within the AstraZeneca global commercial organization (GPPS). Before that, John held a variety of roles across the commercial, strategic and transaction teams at MedImmune. 

John lives in Virginia. He received his MBA from Harvard Business School and his BA from Harvard College. 

Mike is a Director of Inova Personalized Health Accelerator. He is responsible for identifying and investing in all IPHA companies and expediting their achievement of value creating milestones.

As a healthcare technology CEO, Mike raised $125 million in capital and drove shareholder returns that ranged from 4x to 80x, including one IPO and one acquisition. Mike was most recently the founder and CEO of Appian Medical, a digital health firm that served the sleep apnea market. Previously, Mike was CEO of iSonea Ltd (ASX:ISN), a publicly traded global, mobile health app developer and medical device manufacturer in the respiratory disease market, where he increased the company’s market capitalization from $4MM to $250MM.

He is currently a member of the Board of Directors for Circadiance LLC, a specialty CPAP mask manufacturer and is a former board member of AdvaMed, the global medical device association.

Dr. Summar is well-known for his pioneering work in caring for children diagnosed with rare diseases. He joined Children’s National in 2010 from Vanderbilt University. At Children’s National he leads the Division of Genetics and Metabolism, currently the largest known clinical division seeing over 8000 patients a year with rare diseases. Dr. Summar’s laboratory works on both devices and treatments for patients with genetic diseases and adapting knowledge from rare diseases to mainstream medicine. His work has resulted in new drugs in FDA trials for patients with congenital heart disease. His laboratory is best known for its work in the rare diseases affecting nitrogen and ammonia metabolism. Dr. Summar has also organized and led a large number of international work groups to develop standards of care and treatment for rare diseases resulting in significant improvements in outcomes.   Dr. Summar developed a program with NIH where very young children can benefit from NIH research programs at Children’s National. He has been listed with Best Doctor’s in America since 2004. He directs the National Organization for Rare Disorders Scientific and Medical Advisory Committee and leads a program between NORD and the FDA that created a platform for rare disease natural history studies with over 20 already deployed. He is very active in newborn screening issues developing testing and follow-up systems. He has developed and launched at Children’s the world’s first Rare Disease Institute.   This RDI focuses on developing the clinical care field of the over 7000 rare diseases currently recognized. The RDI is the first Clinical Center of Excellence designated by NORD and focuses on building best clinical practices and diagnostic pathways.

Todd Stottlemyer leads the 117-acre Inova Center for Personalized Health campus, which includes the Inova Schar Cancer Institute and the Inova Translational Medicine Institute. Stottlemyer also provides executive leadership for Inova’s research efforts, the Inova Strategic Investment Initiative (venture fund), the Inova Personalized Health Accelerator, Inova’s real estate, and government relations.

Stottlemyer was previously CEO of Acentia, LCC, a private equity backed provider of information technology solutions. Before Acentia, Stottlemyer served as CEO, CFO, and as a member of the executive management teams of three technology companies, two of which were private equity backed and two were publicly traded. Stottlemyer also served as CEO of the National Federation of Independent Business, the nation’s largest business association, and as President of McGuireWoods Consulting.

Stottlemyer has been recognized by Washington Smart CEO magazine as one of their 20 “Most Admired CEOs” in the Washington, DC region; by Washingtonian magazine as one of the Washington, DC region’s top 100 Tech Titans; and by Virginia Business magazine as one of the 50 “most influential Virginians.”

Stottlemyer has served on numerous corporate (publicly traded and private equity and venture backed) and civic boards, including serving as Chair of the Northern Virginia Technology Council (NVTC) and as Chair of the Northern Virginia Chamber of Commerce. Stottlemyer currently serves as Rector (chair) of The College of William & Mary.

Stottlemyer earned his B.A. from The College of William & Mary and a J.D. from the Georgetown University Law Center.

Ben Solomon is a board-certified pediatric geneticist who focuses on the use of genetics and genomics to identify, understand and care for patients with both rare and common genetic conditions as well as broad applications of genomic medicine.  In addition to his laboratory, clinical, and research leadership and advocacy, Dr. Solomon has authored over 100 peer-reviewed articles, book chapters, and textbooks, and is an active lecturer and educator.  Dr. Solomon attended medical school at the Geisel School of Medicine at Dartmouth, completed his residency and fellowship training in pediatrics and clinical genetics at the National Human Genome Research Institute at the National Institutes of Health and at Children’s National Medical Center, and served as Chief of the Division of Medical Genomics at the Inova Translational Medicine Institute.  In 2016, Ben became the head of GeneDx, a large (500+ employee) genetics and genomics laboratory based in Gaithersburg, Maryland.

Bob Silverman leads the “External Drug Discovery Partnering” team of Roche Partnering. Among other matters, Bob is responsible for delivering a structured and systematic approach to venture capital that translates to reach into drug discovery stage innovation via deals originating from venture capital interactions. Prior to his current role, from 2010 – 2012 Bob was a project leader for Merger & Acquisitions, in the Strategic Partnering Group of Roche Partnering. From 2003 – 2010 Bob was a Global Licensing Director for Roche Pharma Partnering, responsible for negotiating intellectual property based licensing agreements across the full value chain of the Pharma business, ranging from enabling technologies and early phase opportunities to clinical stage assets to promoting and divesting marketed products. From 2001 – 2003 Bob was a Global Licensing Attorney. He joined Roche in 1993. Early in his career at Roche Bob was Senior Counsel for the US Affiliate patent department. Bob holds a degree in Chemistry from Franklin & Marshall College and a J.D. from Boston University School of Law, and is a registered patent attorney.

For the past 12 years Dr. Silber has been an active angel investor and strategic advisor in the mid-Atlantic region. He is a Founding Principal of Blu Venture Investors and also a member of the Baltimore Angels. He spent 15 years as an entrepreneur, founding In Vitro Technologies in 1991 and eventually selling it in a successful exit in 2006. He has a PhD in Pharmacology & Toxicology and Masters degree in Public Health. Dr. Silber is the author of numerous publications, holds several patents, is the recipient of numerous business awards and serves on a number of for-profit and nonprofit boards.

Kelly M. Schulz brings a wealth of knowledge to the Maryland Department of Commerce from her years of experience working in the government, in the private sector and as a small business owner. She had previously served as the Secretary of the Maryland Department of Labor, Licensing and Regulation (DLLR) since her confirmation in February 2015 and is also a former member of the Maryland House of Delegates.

At DLLR, she was responsible for managing an agency with nearly 2,000 employees and an operating budget of more than $375 million. Under her leadership, Maryland’s apprenticeship program grew to its highest level since 2008, with more than 10,000 apprentices statewide. DLLR’s Employment Advancement Right Now (EARN) Maryland program received national recognition for both innovation and effectiveness and was named one of the Top 25 programs in the 2018 Innovations in American Government Award competition.

A former member of the Maryland House of Delegates representing Frederick County, she served on the Economic Matters Committee from 2011- 2015. In addition to local issues, then Delegate Schulz took special interest in legislation relating to banks and other financial institutions, business, occupations and professions, economic development, labor and employment, unemployment insurance and workers’ compensation.

Prior to the Department of Commerce, Bret Schreiber has worked for over 20 years in the field of government and community relations, driving policy and economic development initiatives and developing strong ties to local, state and national legislators. As Senior Director for the Office of BioHealth and Life Sciences, Schreiber is working to establish Maryland as the Nation’s premier ecosystem for the BioHealth and Life Science industry.  Previously, as Director of Education and Innovation for the Maryland Department of Commerce, Schreiber worked with Maryland’s Colleges and Universities, and the State’s innovators, entrepreneurs and startups to leverage their economic potential and impact on Maryland’s economic vitality.

Schreiber also served as Director of Governmental and Community Relations for Harford County Maryland,  Vice-president of the Maryland Independent College and University Association (MICUA), leading policy development and involved in organizational operations for Maryland’s 12 independent nonprofit higher education institutions, and also spent 10 years working with the Johns Hopkins Institutions helping to plan, implement, and manage the Johns Hopkins Institutions’ strategic State agenda with elected and appointed officials.  

A Harford County resident, Mr. Schreiber holds a degree in political science from Johns Hopkins University.